Welcome to our dedicated page for FLXN news (Ticker: FLXN), a resource for investors and traders seeking the latest updates and insights on FLXN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FLXN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FLXN's position in the market.
Flexion Therapeutics (Nasdaq:FLXN) has appointed Utpal Koppikar, CFO of Atara Biotherapeutics, to its Board of Directors. Koppikar will also chair Flexion's audit committee. CEO Michael Clayman highlighted Koppikar's extensive biotechnology finance experience as a valuable asset for guiding corporate strategy. Koppikar expressed enthusiasm about supporting the company's management team and advancing its pipeline, including ZILRETTA, an extended-release injectable for osteoarthritis pain. His background includes senior roles at Gilead and Amgen, adding depth to Flexion's executive leadership.
Flexion Therapeutics (Nasdaq:FLXN) announced the grant of 20,440 restricted stock units to five new employees, approved by its Compensation Committee with an effective date of July 1, 2021. These stock units, designed to attract talent, will vest over four years, with 25% vesting annually, contingent on the employees' ongoing service. The grants conform to Nasdaq Listing Rule 5635(c)(4) and are subject to the company's 2013 Equity Incentive Plan.
Flexion Therapeutics (Nasdaq: FLXN) announced that CEO Michael Clayman, M.D., will engage in a fireside chat at the 2021 Raymond James Human Health Innovation Conference on June 21, 2021, at 3:20 p.m. ET. This virtual event will allow investors and analysts to gain insights into the company's focus on developing local therapies for musculoskeletal conditions like osteoarthritis, the most prevalent arthritis type.
For those interested in attending, the live webcast can be accessed through the Flexion Therapeutics website.
Flexion Therapeutics (Nasdaq:FLXN) announced the appointment of William T. Andrews, M.D. as Chief Medical Officer, effective July 1, 2021. Dr. Andrews brings over 20 years of biopharmaceutical experience, previously serving as CMO at Akcea Therapeutics. His role will focus on advancing ZILRETTA for shoulder osteoarthritis and promoting the company’s pipeline. The company is excited about Dr. Andrews' extensive clinical and regulatory expertise, as well as his history of launching new products.
Flexion Therapeutics (Nasdaq:FLXN) announced the granting of 8,510 restricted stock units to five new employees as equity inducement, with an effective date of June 1, 2021. This grant was approved by the Compensation Committee of the Board of Directors, in line with Nasdaq Listing Rule 5635(c)(4). The units will vest over four years, with 25% vesting annually, contingent on continued employment. This move aims to attract and retain talent within the company, which focuses on developing innovative therapies for musculoskeletal conditions, including osteoarthritis.
Flexion Therapeutics (Nasdaq:FLXN) announced that its CEO, Michael Clayman, M.D., will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference. The chat is set for June 8, 2021, at 3:50 p.m. ET. Interested parties can access the live webcast and recordings on the Flexion website. The company specializes in developing therapies for musculoskeletal conditions, notably osteoarthritis.
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that CEO Michael Clayman will participate in an analyst-led fireside chat at the RBC Capital Markets 2021 Virtual Global Healthcare Conference. The event is set for 1:55 p.m. ET on May 19, 2021. Investors and interested parties can access the live webcast and archive via the Flexion website.
Flexion Therapeutics focuses on innovative, local therapies for musculoskeletal conditions, particularly osteoarthritis, enhancing treatment options for patients.
Flexion Therapeutics reported Q1 2021 financial results, highlighting ZILRETTA net sales of $24.6 million, up from $20.1 million year-over-year. The company anticipates full-year ZILRETTA sales between $120 million and $130 million. A net loss of $28.6 million was reported, improved from $36.8 million in Q1 2020. R&D expenses decreased significantly to $14.0 million, while total operating expenses are expected between $195 million and $205 million. Flexion announced management changes, with Fred Driscoll returning as CFO, succeeding David Arkowitz.
Flexion Therapeutics (Nasdaq:FLXN) has granted 18,200 restricted stock units to eight new employees as equity inducement, effective May 3, 2021. This decision was approved by the Compensation Committee and follows Nasdaq Listing Rule 5635(c)(4). The units will vest over four years, contingent on continued employment. The grants align with Flexion's strategic focus on recruiting talent to advance its portfolio of local therapies for musculoskeletal conditions, notably osteoarthritis.
Flexion Therapeutics (Nasdaq:FLXN) will announce its first-quarter 2021 financial results on May 12, 2021, after U.S. market close. A live webcast of the conference call will be accessible via the company’s website, with a replay available afterward. Interested participants can dial in using the provided numbers for domestic and international callers. Flexion focuses on developing innovative local therapies for musculoskeletal conditions, particularly osteoarthritis.
